Minocycline for amyotrophic lateral sclerosis or motor neuron disease
References
Additional references
Almer G, Vukosavic S, Romero N, Przedborski S. Inducible nitric oxide synthase up‐regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. Journal of Neurochemistry 1999;72(6):2415‐25.
Almer G, Guegan C, Teismann P, Naini A, Rosoklija G, Hays AP, et al. Increased expression of the pro‐inflammatory enzyme cyclooxygenase‐2 in amyotrophic lateral sclerosis. Annals of Neurology 2001;49(2):176‐85.
Appel V, Stewart S, Smith G, Appel S. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Annals of Neurology 1987;22(3):328‐33.
Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology 1997;42(4):644‐54.
Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000;1(5):293‐9.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond E, et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Journal of the Neurological Sciences 1999;169(1‐2):13‐21.
Clinical Trials Register. www.clinicaltrials.gov.
Dukes MNG, Aronson JK. Meyler's side effects of drugs. 14th Edition. Elsevier, 2000.
Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, et al. Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology 1997;42(3):326‐34.
Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. New England Journal of Medicine 2003;348(14):1365‐75.
Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al. Placebo‐controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62(10):1845‐7.
Inoue H, Tsukita K, Iwasato T, Suzuki Y, Tomioka M, Tateno M, et al. The crucial role of caspase‐9 in the disease progression of a transgenic ALS mouse model. The EMBO Journal 2003;22(24):6665‐74.
Kriz J, Nguyen MD, Julien J‐P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease 2002;10(3):268‐78.
Kriz J, Gowing G, Julien J‐P. Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase. Annals of Neurology 2003;53(4):429‐36.
McGuire D, Garrison L, Miller RG. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. Neurology 1996;46(5):1442‐4.
Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2007, Issue 2.
Norris FH, Calanchini PR, Fallat R, Panchri S, Jewett BJ. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974;24(8):721‐8.
Pasinelli P, Houseweart MK, Brown RH, Cleveland DW. Caspase‐1 and ‐3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase‐mediated familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2000;97(25):13901‐6.
Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurological Sciences 2005;26(4):285‐7.
Rowland LP, Schneider NA. Amyotrophic lateral sclerosis. New England Journal of Medicine 2001;344(22):1688‐99.
Sathasivam S, Grierson AJ, Shaw PJ. Characterization of the caspase cascade in a cell culture model of SOD1‐related familial amyotrophic lateral sclerosis: expression, activation and therapeutic effects of inhibition. Neuropathology and Applied Neurobiology 2005;31(5):467‐85.
Shaw PJ. Motor neurone disease. British Medical Journal 1999;318(7191):1118‐21.
Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. Journal of Neurology, Neurosurgery and Psychiatry 2005;76(8):1046‐57.
Tikka TM, Vartiainen NE, Goldsteins G, Oja SS, Andersen PM, Marklund SL, Koistinaho J. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002;125(4):722‐31.
Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, Giorgini A, et al. Persistent activation of p38 mitogen‐activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Molecular and Cellular Neurosciences 2003;23(2):180‐92.
Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13(8):1067‐70.
Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. Journal of the Neurological Sciences 2001;191(1‐2):3‐9.
Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurology 2004;3(12):744‐51.
Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Annals of Neurology 2003;53(2):267‐70.
Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417(6884):74‐8.
